Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Clinical Trial Tool Launched to Speed Amyloidosis Drug Development

By Amyloidosis Research Consortium | March 9, 2017

The Amyloidosis Research Consortium, in partnership with Patient Discovery Solutions, launches a rare disease clinical trial matching tool to accelerate drug development in amyloidosis.

In a recent Amyloidosis Research Consortium (ARC) patient study, 79 percent of patients said with better information and access they would consider participating in a clinical trial. The major obstacles which prevent patients from participating in clinical trials were cited as the lack of education about clinical trials, complexities of accessing information about trials, and the use of overly scientific language.

“The inability to complete trials in a timely manner delays the approval of potentially effective treatments, it represents a huge barrier to the development of much needed treatments for rare diseases such as amyloidosis where no there are no FDA approved therapies,” says Isabelle Lousada, CEO ARC, “It ultimately blocks progress and our path to a cure.”

To address patients’ concerns and break down the barriers to participation in clinical research, ARC partnered with Patient Discovery to co-innovate on MAP.  MAP is a data-driven clinical trial tool which intelligently matches patients with clinical trials and treatment centers. 

“This tool provides early engagement and educational components, empowering patients with a greater understanding of the value of participating in clinical trials,” says Shelby Chamberlain, co-founder of Patient Discovery. “It was developed with the input from a diverse team of stakeholders, including clinical researchers, patient advocates, and representatives from pharmaceutical companies.  We are excited to use this tool to help other patient populations within the rare disease community.”

“We believe MAP provides a much needed tool for amyloidosis,” Lousada states. “The anonymized data collected by MAP can inform clinical trial design; by meeting patient needs they will accrue faster, better serve the patient community, and ultimately contribute to accelerating much needed therapies for amyloidosis.”

Systemic amyloidosis comprise a number of rare and fatal diseases caused by the misfolding of proteins and characterized by progressive organ damages. These misfolded proteins aggregate and deposit in multiple vital organs and systems (e.g., heart, kidneys, nervous system), causing significant morbidity and mortality.

(Source: PR Newswire)


Filed Under: Drug Discovery

 

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50